Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood–cerebrospinal fluid barrier in human brain

[1]  H. Edlund,et al.  Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance* , 2015, The Journal of Biological Chemistry.

[2]  A. Castañeyra-Perdomo,et al.  Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer’s disease , 2015, Front. Cell. Neurosci..

[3]  Yoichi Chiba,et al.  Clearance of beta-amyloid in the brain. , 2014, Current medicinal chemistry.

[4]  Thomas Brinker,et al.  A new look at cerebrospinal fluid circulation , 2014, Fluids and Barriers of the CNS.

[5]  Xiren Gao,et al.  Amyloid-beta transporter expression at the choroid plexus in normal aging: the possibility of reduced resistance to oxidative stress insults. , 2014, Sheng li xue bao : [Acta physiologica Sinica].

[6]  D. Strickland,et al.  Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity. , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Tall,et al.  ATP-binding cassette transporters, atherosclerosis, and inflammation. , 2014, Circulation research.

[8]  D. Holtzman,et al.  Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1 , 2013, The Journal of Neuroscience.

[9]  L. Fenart,et al.  Amyloid-β peptides, Alzheimer's disease and the blood-brain barrier. , 2013, Current Alzheimer research.

[10]  Y. Chan,et al.  A pilot study on low-density lipoprotein receptor-related protein-1 in Chinese patients with abdominal aortic aneurysm. , 2013, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[11]  Y. Marcel,et al.  Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[12]  R O Weller,et al.  Review: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy , 2013, Neuropathology and applied neurobiology.

[13]  G. Landreth,et al.  Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[14]  Michael T. Heneka,et al.  PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice , 2012, The Journal of Neuroscience.

[15]  A. Kaddoumi,et al.  Role of ABC transporters in the pathogenesis of Alzheimer's disease. , 2012, ACS chemical neuroscience.

[16]  Jie Li,et al.  LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-β , 2012, The Journal of Neuroscience.

[17]  S. Love,et al.  LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status , 2012, Neuroscience Letters.

[18]  Tim West,et al.  Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis , 2012, Proceedings of the National Academy of Sciences.

[19]  D. Hermann,et al.  Liver X Receptor Activation Enhances Blood–Brain Barrier Integrity in the Ischemic Brain and Increases the Abundance of ATP‐Binding Cassette Transporters ABCB1 and ABCC1 on Brain Capillary Cells , 2012, Brain pathology.

[20]  D. Holtzman,et al.  Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of Aβ Uptake and Degradation by Astrocytes* , 2012, The Journal of Biological Chemistry.

[21]  D. Maślińska,et al.  Immunodistribution of amyloid beta protein (Aβ) and advanced glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients. , 2011, Folia neuropathologica.

[22]  Andreas Wree,et al.  Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. , 2011, The Journal of clinical investigation.

[23]  T. Iwatsubo,et al.  Amyloid‐β peptide(1‐40) elimination from cerebrospinal fluid involves low‐density lipoprotein receptor‐related protein 1 at the blood‐cerebrospinal fluid barrier , 2011, Journal of neurochemistry.

[24]  Miles C. Miller,et al.  Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent , 2011, Fluids and Barriers of the CNS.

[25]  A. Fagan,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[26]  Yansheng Du,et al.  Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice , 2011, Neuroscience Letters.

[27]  R. Bateman,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[28]  Yanshu Zhang,et al.  Lead-induced accumulation of beta-amyloid in the choroid plexus: role of low density lipoprotein receptor protein-1 and protein kinase C. , 2010, Neurotoxicology.

[29]  G. Landreth,et al.  The role of microglia in amyloid clearance from the AD brain , 2010, Journal of Neural Transmission.

[30]  F. Kronenberg,et al.  Sex and age interaction with genetic association of atherogenic uric acid concentrations. , 2010, Atherosclerosis.

[31]  T. Terasaki,et al.  Lack of brain‐to‐blood efflux transport activity of low‐density lipoprotein receptor‐related protein‐1 (LRP‐1) for amyloid‐β peptide(1–40) in mouse: involvement of an LRP‐1‐independent pathway , 2010, Journal of neurochemistry.

[32]  M. Götz,et al.  LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche , 2010, Journal of Cell Science.

[33]  D. Holtzman,et al.  Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance , 2009, Neuron.

[34]  Yanshu Zhang,et al.  Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure , 2009, Cerebrospinal Fluid Research.

[35]  Paolo Maria Rossini,et al.  Validation of Alzheimer’s disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI) , 2009, Experimental Gerontology.

[36]  L. Lue,et al.  ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides , 2009, The Journal of Neuroscience.

[37]  I. Romero,et al.  P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid-β , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  R. Mendez-Otero,et al.  Radial glia-like cells persist in the adult rat brain , 2009, Brain Research.

[39]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[40]  J. Rafols,et al.  Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis , 2008, Brain Research.

[41]  J. Ghersi-Egea,et al.  Differential expression of the multidrug resistance‐related proteins ABCb1 and ABCc1 between blood‐brain interfaces , 2008, The Journal of comparative neurology.

[42]  J. García-Verdugo,et al.  Neural stem cells confer unique pinwheel architecture to the ventricular surface in neurogenic regions of the adult brain. , 2008, Cell stem cell.

[43]  J. Watchko,et al.  ABC Transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) Expression in the Developing Human CNS , 2008, Neuropediatrics.

[44]  Christopher M Waters,et al.  Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. , 2008, American journal of physiology. Cell physiology.

[45]  M. Dietrich,et al.  Megalin mediates the transport of leptin across the blood-CSF barrier , 2008, Neurobiology of Aging.

[46]  T. Iwatsubo,et al.  ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-β peptide (1–40) at the blood–brain barrier , 2008, Neurochemistry International.

[47]  R. Carare,et al.  Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. , 2008, Brain pathology.

[48]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[49]  R. Carare,et al.  SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Perivascular Drainage of Amyloid‐β Peptides from the Brain and Its Failure in Cerebral Amyloid Angiopathy and Alzheimer's Disease , 2007 .

[50]  M. Verbeek,et al.  Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. , 2007, The American journal of pathology.

[51]  R. Wilensky,et al.  The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation , 2007, Current opinion in cardiology.

[52]  A. Lusis,et al.  Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE , 2007 .

[53]  Wei Zheng,et al.  Macromolecules involved in production and metabolism of beta-amyl oid at the brain barriers , 2007, Brain Research.

[54]  T. Terasaki,et al.  24S‐hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical‐ and apoE isoform‐dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression , 2007, Journal of neurochemistry.

[55]  G. Silverberg,et al.  Expression of the beta-amyloid transporter, LRP-1, in aging choroid plexus: implications for the CSF-brain system in NPH and Alzheimer's disease , 2006, Cerebrospinal Fluid Research.

[56]  K. Fukuchi,et al.  Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice , 2006, Neurobiology of Aging.

[57]  Yasir Abdulkarim,et al.  Is the LDL Receptor Involved in Cortical Amyloid Protein Clearance? , 2006, Neurochemical Research.

[58]  J. Ghersi-Egea,et al.  Brain Protection at the Blood–Cerebrospinal Fluid Interface Involves a Glutathione-Dependent Metabolic Barrier Mechanism , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[59]  Mathias Jucker,et al.  Mechanism of Cerebral β‐Amyloid Angiopathy: Murine and Cellular Models , 2006 .

[60]  I. Torres-Aleman,et al.  Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I , 2005, The Journal of Neuroscience.

[61]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[62]  Wei Zheng,et al.  The Choroid Plexus Removes β-Amyloid from Brain Cerebrospinal Fluid , 2005 .

[63]  Masahiko Watanabe,et al.  Distinct spatio‐temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain , 2005, Journal of neurochemistry.

[64]  D. Holtzman,et al.  The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice* , 2005, Journal of Biological Chemistry.

[65]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[66]  R. Deane,et al.  RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.

[67]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[68]  M. Rausch,et al.  Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis , 2004, The European journal of neuroscience.

[69]  Q. Yao,et al.  Cellular and molecular mechanisms of atherosclerosis with mouse models. , 2004, Trends in cardiovascular medicine.

[70]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[71]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[72]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[73]  G. Silverberg,et al.  Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis , 2003, The Lancet Neurology.

[74]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[75]  W. Gong,et al.  Potential role of the formyl peptide receptor‐like 1 (FPRL1) in inflammatory aspects of Alzheimer’s disease , 2002, Journal of leukocyte biology.

[76]  R. Silverstein,et al.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.

[77]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[78]  W. Shen,et al.  Amyloid β42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1 , 2001, The Journal of Neuroscience.

[79]  C. Frassoni,et al.  Organization of radial and non‐radial glia in the developing rat thalamus , 2000, The Journal of comparative neurology.

[80]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[81]  M. Ueno,et al.  Blood-brain barrier permeability in the periventricular areas of the normal mouse brain , 2000, Acta Neuropathologica.

[82]  D D Breimer,et al.  Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.

[83]  H. Kusuhara,et al.  Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[84]  Y. Sugiyama,et al.  Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein. , 1999, The Journal of pharmacology and experimental therapeutics.

[85]  C. Finch,et al.  Glycoprotein 330/Megalin (LRP-2) Has Low Prevalence as mRNA and Protein in Brain Microvessels and Choroid Plexus , 1999, Experimental Neurology.

[86]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[88]  S. Ranganathan,et al.  Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. , 1997, The Journal of biological chemistry.

[89]  M. Ueno,et al.  Age-related changes in the brain transfer of blood-borne horseradish peroxidase in the hippocampus of senescence-accelerated mouse , 1997, Acta Neuropathologica.

[90]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.

[91]  E. Matsubara,et al.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[92]  D. Greenwalt,et al.  Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. , 1995, The Journal of clinical investigation.

[93]  D. Strickland,et al.  Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39 kDa receptor associated protein in embryonic mouse tissues. , 1994, In vivo.

[94]  I. Stamenkovic,et al.  Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[95]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[96]  R. Keep,et al.  A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. , 1990, Brain research. Developmental brain research.

[97]  J. Kaye,et al.  Cerebrospinal fluid production is reduced in healthy aging , 1990, Neurology.

[98]  Miyuki Yamamoto,et al.  Cortical radial glia: identification in tissue culture and evidence for their transformation to astrocytes , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[99]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[100]  K. Weber,et al.  Vimentin, the 57 000 molecular weight protein of fibroblast filaments, is the major cytoskeletal component in immature glia. , 1981, European journal of cell biology.

[101]  F. Calon,et al.  ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. , 2012, Journal of Alzheimer's disease : JAD.

[102]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[103]  R. Carare,et al.  Lymphatic drainage of the brain and the pathophysiology of neurological disease , 2008, Acta Neuropathologica.

[104]  A. Lusis,et al.  Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. , 2007, The Journal of clinical investigation.

[105]  Ji Ming Wang,et al.  Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in alzheimer disease , 2005, Immunologic research.

[106]  Wei Zheng,et al.  The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. , 2005, Experimental biology and medicine.

[107]  J. Berman,et al.  CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. , 2002, The American journal of pathology.

[108]  V. Ferrans,et al.  Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  P. Reiner,et al.  beta-Amyloid efflux mediated by p-glycoprotein. , 2001, Journal of neurochemistry.

[110]  F. Balis,et al.  Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates , 2000, Cancer Chemotherapy and Pharmacology.